Cardiovascular Medicine and Haematology articles for Harvard University, United States of America (USA)

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 245

Article ‘Count’ for Cardiovascular Medicine and Haematology.

Journal Count Share
1 0.19
Reprogramming Lesional Macrophage Homeostasis via Interferon Regulatory Factor 5 Targeted siRNA Nanoimmunotherapy for Atherosclerosis 0.19
1 0.31
A Vascular Microphysiological Model of Lung Fibrosis Reveals That Myofibroblasts and IPF Patient‐Derived Fibroblasts Impair Angiogenesis and Vasculogenesis 0.31
1 0.75
Gut microbiota-derived pro-inflammatory biomarkers and risk of coronary artery disease: a prospective study among US men and women 0.75
1 0.43
Use of censored data methods to estimate blood pressure percentiles in US adults 0.43
17 2.94
Astegolimab for COPD With Frequent Exacerbations: Pooled Analysis of the ALIENTO and ARNASA Trials 0.06
Single-cell Sequencing Unveils A Profibrotic Macrophage and Infiltrating Monocyte Niche in the Bronchoalveolar Lavage of Patients with Chronic Obstructive Pulmonary Disease 0.13
Sub-phenotypes of pneumonia defined by pulmonary histopathological features 0.11
Idiopathic Pulmonary Fibrosis Risk Loci in East Asian Populations Mirror those of European Populations 0.02
Mosaic Loss of Y chromosome associates with lung function, emphysema and epigenetic aging 0.23
Discriminative Performance and Clinical utility of COPD Exacerbation Categories for Predicting Future Exacerbations 0.27
Pulmonary Rehabilitation is Associated with Increased 1-Year Survival in Stable COPD 0.07
Mucus Plugs-associated Gene Expression Identifies Pathophysiology Shared with Chronic Bronchitis. 0.57
Impact of Sleep Apnea on Perivascular Diffusivity and Cognition: A 4-Year Prospective Cohort Study. 0.08
Visual and Quantitative Interstitial Lung Abnormality Progression in COPDGene. 0.76
Molecular Phenotyping of Sepsis and Differential Response to Fluid Resuscitation. 0.06
Lipid Ratios for Diagnosis and Prognosis of Pulmonary Hypertension 0.02
Associations of Prepandemic Lung Function and Structure with COVID-19 Outcomes: The C4R Study 0.06
Dual αvβ6 and αvβ1 Inhibition over 12 Weeks Reduces Active Type I Collagen Deposition in Individuals with Idiopathic Pulmonary Fibrosis: A Phase 2, Double-Blind, Placebo-controlled Clinical Trial 0.37
Metabolomic Evidence of Biological Overlap with HFpEF in a Subset of Pulmonary Arterial Hypertension. 0.05
Deficient FANCL Predisposes Endothelial Damage: A New Therapeutic Target for Pulmonary Hypertension. 0.03
<atl>Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in iBMPR2/i Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR)</atl> 0.05
2 0.54
Intraoperative Cardiac Events in Pediatric Patients with Congenital Heart Disease Undergoing Noncardiac Procedures: Analysis of a Large Multicenter Registry. 0.37
TEG® 6s heparin neutralization cartridge for hemostatic assessment of patients undergoing cardiovascular surgery. 0.17
1 0.83
Effect of Systolic Blood Pressure Measurement Error on the Cost-Effectiveness of Intensive Blood Pressure Targets. 0.83
1 0.06
<atl>Prospective, Multicenter Evaluation of Transcarotid Artery Revascularization in Standard‐Risk Patients: 30‐Day Outcomes of the scpROADSTER/scp 3 Study</atl> 0.06
2 1.06
Randomized Controlled Trial of New Oral Anticoagulants Versus Warfarin for Post Cardiac Surgery Atrial Fibrillation: The NEWAF Trial. 1.00
Transcarotid Artery Revascularization Versus Carotid Endarterectomy With and Without High-Risk Criteria: A National Target Trial. 0.06
3 1.73
Glucagon‐Like Peptide‐1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients with Systemic Lupus Erythematosus and Lupus Nephritis 1.00
Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis 0.13
Comparative Cardiovascular Safety of Nonsteroidal Anti‐Inflammatory Drug Versus Colchicine Use When Initiating Urate‐Lowering Therapy Among Patients With Gout: Target Trial Emulations 0.60
3 0.89
Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia 0.85
A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study 0.03
Modeling the HLH immune synapse uncovers critical roles for IS termination, cytokine intensity, and target cell death 0.00
1 0.20
Development of a standard definition of ‘no-option’ and ‘poor-option’ for revascularization in chronic limb-threatening ischemia 0.20
1 0.26
An infant nasal microbial gene atlas uncovers intervention-driven microbiome shifts and salt-resistant pathogen expansion 0.26
7 2.33
Efficacy of Anti-Inflammatory Therapies for Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and Network Meta-Analysis 0.11
From Pulse to Phenotype: Sleep Apnea Endotyping for Polygraphy via Oximeter-derived Autonomic Arousal 0.20
Cardiovascular Events in COPD: Complementary Role of Cardiac Risk and Coronary Artery Calcium Scores 0.15
Acetazolamide plus Atomoxetine for Obesity Hypoventilation Syndrome Treatment A Randomized Controlled Trial 0.05
Lung Function Changes Across the Menopausal Transition: A Longitudinal Analysis of Annual Exams 0.26
Hypoxic Burden is Associated with Cardiovascular Events: A Risk Stratification Analysis of the RICCADSA Cohort 0.70
Anti-Ro52 Seropositive Interstitial Lung Disease is Associated with a Higher Risk for Disease Progression and Mortality 0.86
31 7.94
Integrative Molecular Analyses of Inflammatory and Autoimmune Signals in Cardiac Sarcoidosis 0.65
Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial 0.35
Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior Myocardial Infarction: Results From the VESALIUS-CV Trial 0.29
The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis. 0.11
Cardiovascular-Kidney-Metabolic Syndrome Stages, Echocardiographic Characteristics, and Heart Failure Risk: The Atherosclerosis Risk in Communities Study. 0.39
The Fontan Outcomes Network: Findings After 2 Years and 1121 Participants. 0.05
Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy. 0.18
Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension. 0.05
Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin. 0.54
Association of Pre-Fontan Hemodynamics With Long-Term Outcomes After Fontan Palliation: A Study From the Pediatric Cardiac Care Consortium 0.04
CXCR6+ T Cells Drive Immune Checkpoint Inhibitor Myocarditis. 0.13
IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes. 0.20
Leveraging a Genetic Proxy to Investigate the Effects of Lifelong Cardiac Sodium Channel Blockade. 0.19
Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial. 0.04
Incidence, Risk Factors, and Outcomes in Stressor-Associated Atrial Fibrillation: Insights from the VITAL-AF Trial 0.75
Efficacy and Safety of Very Low Achieved LDL-Cholesterol in Patients with Prior Ischemic Stroke. 0.46
IRF5 siRNA Nanoimmunotherapy: Restoring Macrophage Efferocytosis in Atherosclerosis. 0.25
Heart Stress and Blood Pressure Management in Older Adults: Post Hoc Analysis of the ASPREE Trial. 0.02
Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial. 0.63
Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA 0.08
Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure. 0.43
Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. 0.02
Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants. 0.03
Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induced Cardiomyopathy. 0.03
TBX5 and CHD4 Coordinately Activate Atrial Cardiomyocyte Genes to Maintain Cardiac Rhythm Homeostasis. 0.77
Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke. 0.02
Evaluation of Lipoprotein(a) as a Prognostic Marker of Extracoronary Atherosclerotic Vascular Disease Progression. 0.69
The Impact of Fontan Circulatory Failure on Heart Transplant Survival: A 20-Center Retrospective Cohort Study. 0.04
Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial. 0.47
Burden of Cardiovascular Outcomes After SARS-CoV-2 Infection in South Korea and Japan: A Binational Population-Based Cohort Study. 0.04
Aortic Aneurysm Risk and Somatic JAK2V617FVariation: Insights From a Multicenter, Population-Based Cardiovascular Screening Study. 0.01
3 1.89
Associations between antibiotic use and outcomes in patients hospitalized with community-acquired pneumonia and positive respiratory viral assays 0.48
Risk Assessment in a Global CVD Prevention Cohort of People with HIV by PCE, PREVENT, and SCORE2 0.58
Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings 0.83
4 1.03
Socioeconomic Factors and Initiation of Semaglutide or Tirzepatide Among Medicare Beneficiaries With Type 2 Diabetes. 0.57
Screening Natriuretic Peptide Levels Predicts Heart Failure and Death in Individuals With Type 1 and Type 2 Diabetes Without Known Heart Failure. 0.17
Racial Inequity in Prescription of Semaglutide Among Eligible People With HIV 0.04
Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial. 0.25
1 0.25
A longitudinal cohort study of damp and mouldy housing and children's respiratory health in Bradford, UK 0.25
1 1.00
Evaluating heterogeneity in the impact of the reformulated gasoline program on childhood and young adult lymphoma incidence: A Bayesian causal inference analysis 1.00
1 0.06
Human Health Impacts of Energy Transitions across the United States among Sociodemographic Subpopulations for the Year 2050 0.06
17 3.48
Sex differences in cardiovascular–kidney–metabolic syndrome: the FINE-HEART pooled analysis 0.24
Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model 0.01
Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model 0.02
Laminopathies: natural history and risk prediction of heart failure 0.01
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study 0.09
Foundation models for electrocardiogram interpretation: clinical implications 0.07
Combined clinical, metabolomic, and polygenic scores for cardiovascular risk prediction 0.01
Sex-specific cardiac ageing and sympathetic compensation: a translational study 0.01
Women with chronic coronary artery disease: long-term outcomes after percutaneous coronary intervention vs coronary artery bypass grafting 0.11
Artificial intelligence-enhanced electrocardiography to predict regurgitant valvular heart diseases: an international study 0.11
Drug-coated vs non-drug-coated devices for femoropopliteal artery interventions: long-term outcomes of the SAFE-PAD study 1.00
C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the ‘SMuRF-less but inflamed’ 0.80
Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial 0.03
Titin-related familial dilated cardiomyopathy: factors associated with disease onset 0.05
Cardiovascular benefit of continuous positive airway pressure according to high-risk obstructive sleep apnoea: a multi-trial analysis 0.53
Radial vs femoral access for percutaneous coronary intervention: temporal trends and outcomes in the USA 0.33
Immune checkpoint inhibitor-associated myocarditis: a novel risk score 0.06
1 0.40
Regeneration alters open chromatin and cis-regulatory landscape of erythroid precursors 0.40
2 0.54
Influenza hijacks myeloid cells to inflict type-I interferon-fueled damage in the heart 0.09
Epigenetic silencing of interleukin-10 by host-derived oxidized phospholipids supports a lethal inflammatory response to infections 0.45
1 0.75
Comparative Effectiveness and Safety of LAMA-LABA Inhalers in Chronic Obstructive Pulmonary Disease 0.75
1 0.78
Z-Drug Use in the First Trimester of Pregnancy and Risk of Congenital Malformations 0.78
6 0.68
Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy 0.05
Real-World Outcomes of Transcatheter Tricuspid Valve Replacement 0.07
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes 0.01
Familial Hypercholesterolemia Screening in Childhood and Early Adulthood 0.22
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria 0.18
Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria 0.15
1 0.55
Inflamed endothelial cells express S1PR1 inhibitor CD69 to induce vascular leak 0.55
2 0.71
Lipoprotein(a)-Associated Proteomic Signature Predicts Cardiovascular Disease in Young Adults 0.07
A CD57+ CD8 T cell subset links cytotoxic T cell cytotoxicity to fibrotic lung disease in systemic sclerosis 0.63
2 0.11
Health Outcomes Beyond Age 50 Years in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. 0.06
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results. 0.05
1 0.32
Inflammatory macrophages associate with tissue injury and fibrosis in a mouse model of tuberculosis 0.32
1 0.10
Evidence for acid‐sensing ion channel 3 (ASIC3) involvement in cough resulting from aspiration of gastric fluid 0.10
9 5.30
Ten-year outcomes of valve-replacing versus valve-sparing aortic root replacement in Marfan syndrome patients: An observational multicenter study 0.08
A Prospective, Multicenter Trial of Irrigated Radiofrequency Ablation and Cryoablation to Treat Non-Paroxysmal Atrial Fibrillation 0.09
Multi-Center Comparison of Hybrid and Norwood Procedure in Patients with Fontan Circulation 0.06
Pathology of Explanted Novel ePTFE Pulmonary Valved Conduits Reveals Paucity of Leaflet Tissue Response but Frequent Non-Adherent Thrombus Formation 1.00
Primary biventricular repair in neonates with borderline left ventricle 1.00
Iatrogenic aortic dissection: Insights from the International Registry of Acute Aortic Dissection 0.06
Growth of the Fontan Pathway and its Association with Long-Term Outcomes 1.00
Outcomes Following Repair of Truncus Arteriosus with Interrupted Aortic Arch 1.00
Neo-aortic valve regurgitation and root dilation after arterial switch operation in patients with native left ventricular outflow tract obstruction 1.00
37 10.08
ECG Signatures and Long-Term Ischemic Stroke Risk A Deep Learning Analysis of 200,000 Patients 0.69
Aligning Coronary Stent Trial Enrollment With the U.S. Intended-Use Population 0.02
Body Mass Index, Clinical Outcomes, and Mortality in Heart Failure: A Mendelian Randomization Study 0.10
Midlife Cardiorespiratory Fitness and Healthy Aging 0.10
Sirolimus-Eluting Balloon vs Repeat Drug-Eluting Stent or Balloon Angioplasty for Coronary In-Stent Restenosis 0.14
Risk-Guided Atrial Fibrillation Screening With Artificial Intelligence–Enabled Electrocardiogram Models 0.79
Opportunistic Cardiovascular Risk Assessment Using Routine Head CT in the Emergency Department 0.33
Combining Genomics With Lipid and Inflammatory Biomarkers to Predict Coronary Artery Disease Risk 0.76
Comparative Prognosis of Chagas and Other Cardiomyopathies 0.13
Interchangeability of the KCCQ-12 and KCCQ-23 across gt;18,000 Participants Enrolled in 4 Large-Scale Trials of Heart Failure 0.46
Single-Ventricle Disease 0.06
Pulsed Field Ablation vs Standard Radiofrequency Ablation for Typical Atrial Flutter: ADVANTAGE AF Trial Substudy 0.05
Hospitalizations and Mortality Among Medicare Beneficiaries at Cardiovascular Risk Disruptions and Recovery From the COVID-19 Pandemic 0.50
Association of Lp(a) With Cardiovascular Disease and All-Cause Mortality in U.S. Hispanics and Latinos 0.05
Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023 0.71
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multi-Domain, Patient-Level Analysis of the MAPLE-HCM Trial 0.19
Proactive Management and Treatment of Aortic Stenosis: An International Expert Perspective 0.03
Multicenter Study on the Safety of Pulsed Field Ablation in Over 40,000 Patients: MANIFEST-US 0.03
Using Artificial Intelligence to Adjudicate Major Adverse Cardiovascular Events in Clinical Trials 0.65
Very High Prevalence of Nonoptimally Controlled Traditional Risk Factors at the Onset of Cardiovascular Disease 0.06
Danicamtiv, a selective agonist of cardiac myosin, for dilated cardiomyopathy: A Phase 2 open-label trial 0.13
Left Ventricular Health and TAVR Timing in Asymptomatic Severe Aortic Stenosis: Analysis from the EARLY TAVR Trial 0.06
Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation Results in 18,000 Clinical Trial Participants 0.47
Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis: An Exploratory Substudy of the LoDoCo2 Trial 0.21
Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of Three Global Trials 0.21
Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection Fraction 0.44
Effect of Aficamten Compared with Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM 0.20
A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk 0.88
Prevalence and Predictors of Neurocognitive Dysfunction in Adults With Congenital Heart Disease Results From MINDS-ACHD 0.05
Paclitaxel-Coated Balloon for the Treatment of Multilayer In-Stent Restenosis AGENT IDE Subgroup Analysis 0.04
Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure With Improved Ejection Fraction 0.06
Global Impact of Fixed-Dose Combination Therapies on Cardiovascular Mortality and Events, 2023-2050 A Modeling Study 0.08
AHA PREVENT Equations and Cardiovascular Disease Risk in Diverse Health Care Populations 0.38
Plaque Vulnerability and Cardiovascular Risk Factor Burden in Acute Coronary Syndrome An Optical Coherence Tomography Analysis 0.45
Differences in Arterial Events in Vascular Ehlers-Danlos, Loeys-Dietz, and Marfan Syndrome 0.04
Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension Results of an International Multicenter Prospective Registry 0.03
Long-Acting Factor XI Inhibition and Periprocedural Bleeding An Analysis From AZALEA-TIMI 71 0.53
4 1.73
Outcomes After Percutaneous Coronary Intervention for Chronic Coronary Disease in Adults ≥ 75 versus lt; 75 Years 0.13
Post‐Stroke Atrial Fibrillation Detection With Insertable Cardiac Monitors in Patients With Dementia and Frailty 0.73
Patterns of Oral Anticoagulant Use in Atrial Fibrillation Following Transition to Long‐Term Care 0.81
Advancing Age and Risk From the Elevated Atherogenic Index: Triglyceride (TG) to High‐Density Cholesterol (HDL‐C) Ratio 0.05
2 0.14
Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone. 0.06
Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial. 0.08
16 2.68
Metabolic and inflammatory biomarker trajectories after a cancer diagnosis and the risk of cardiovascular diseases 0.12
Gene-gene interactions between a LMNA variant and common polymorphisms drive early-onset atrial fibrillation 0.02
Joint clinical and molecular subtyping of COPD with variational autoencoders 0.91
Cuffless hemodynamic monitoring with physics-informed machine learning models 0.13
Chromatin rewiring of β-globin and MYC enhancers by TGF-β1 drives defective erythropoiesis 0.03
Osteoarthritis and analgesic consumption in haemochromatosis HFE C282Y homozygotes with normal or low iron parameters 0.06
Activation of IRF3 in cardiomyocytes impairs mitochondrial oxidative function through PGC-1α inhibition and drives heart failure 0.03
Expert-level probabilistic breathing event detector informs phenotyping of sleep apnea 0.18
Hic-5 drives epithelial mechanotransduction promoting a feed-forward cycle of bronchoconstriction 0.73
Modifiable influencing factors and their joint effects on early- and late-onset coronary heart disease 0.20
Risk factors for mortality in patients with kidney failure on hemodialysis identified by proteomic analysis of CRIC and PACE studies 0.03
Genome-wide analysis of heart failure yields insights into disease heterogeneity and enables prognostic prediction in the Japanese population 0.06
Integrated multiomics of pressure overload in the human heart prioritizes targets relevant to heart failure 0.06
Association between self-reported multimorbidity and longitudinal brain Aβ deposition in Alzheimer’s disease 0.02
Metabolic reprogramming of the neovascular niche promotes regenerative angiogenesis in proliferative retinopathy 0.06
Global warming may increase the burden of obstructive sleep apnea 0.07
10 1.88
The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial 0.07
The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial 0.25
Pulsed Field Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation: 4-Year Outcomes in the Study 0.10
Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial 0.17
The NOTCH3 extracellular domain is a serum biomarker for pulmonary arterial hypertension 0.07
Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study 0.01
Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice 0.83
Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial 0.29
AI-based diagnosis of acute aortic syndrome from noncontrast CT 0.02
Performance of the American Heart Association’s PREVENT risk score for cardiovascular risk prediction in a multiethnic population 0.08
1 0.20
Mouse radial spoke 3 is a metabolic and regulatory hub in cilia 0.20
1 0.09
Effect of climate-driven childhood sleep erosion on potential regional economic inequality 0.09
2 1.02
Cholinergic signaling modulates intestinal pathophysiology in a drosophila model of cystic fibrosis 1.00
MYH11 rare variant augments aortic growth and induces cardiac hypertrophy and heart failure with pressure overload 0.02
3 1.85
Calumenin prevents fibroblast senescence and lung aging by promoting vimentin proteostasis 0.04
Dynamic regulation of receptor-modulated endothelial NADPH oxidases 0.81
Platelets engage mast cells in a bilateral IL-33-driven feed-forward loop 1.00
2 1.01
Deep-learning analysis of 3D microarchitectural remodeling in hypertrophic cardiomyopathy 0.39
Resistin-like molecule γ attacks cardiomyocyte membranes and promotes ventricular tachycardia 0.62
1 0.26
Design and preclinical feasibility of a pediatric heart valve stent that spontaneously adapts to growth via a spring mechanism 0.26
6 1.16
Natural killer cell immunotherapy reverses lung fibrosis by eliminating senescent fibroblasts 0.13
Lactate transport inhibition therapeutically reprograms fibroblast metabolism in experimental pulmonary fibrosis 0.66
Inhibition of CXCL10 and IFN-γ ameliorates myocarditis in preclinical models of SARS-CoV-2 mRNA vaccination 0.06
Engraftment and persistence of HBB base-edited hematopoietic stem cells in nonhuman primates 0.10
Complement is activated in patients with acute chest syndrome caused by sickle cell disease and represents a therapeutic target 0.12
Regulatory T cells attenuate chronic inflammation and cardiac fibrosis in hypertrophic cardiomyopathy 0.08
2 1.02
Impact of shifting blood donation policy from gift to honour model: staggered difference-in-differences analysis in China 0.02
Continued versus discontinued oral anticoagulant treatment for unprovoked venous thromboembolism: target trial emulation 1.00
8 3.28
Associations of rurality, child opportunity, and distance with use of pediatric asthma specialists 0.20
Predicting Asthma Prevalence Across U.S. Communities by Integrating Social Vulnerability and Environmental Risk with Machine Learning 0.83
Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years 0.08
Blood neutrophil genetics highlight the role of neutrophils in early childhood asthma and viral respiratory illnesses 0.02
Differential effects of subcutaneous and sublingual immunotherapy on timothy grass–specific TH2 CD4+ T-cell subsets 0.08
Platelet-macrophage cooperation drives IL-33-dependent type 2 lung immunopathology in a sex-biased manner 1.00
Reduced ALDH2 in the respiratory tract associates with dysregulated alcohol metabolism and respiratory reactions in AERD 1.00
Impact of Nasal and Inhaled Corticosteroids on SARS-CoV-2 Infection Susceptibility 0.06
3 0.09
Transcatheter aortic valve implantation with the Trilogy valve for symptomatic native aortic regurgitation (ALIGN-AR): a pivotal, multicentre, single-arm, investigational device exemption study 0.04
Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials 0.01
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial 0.04
1 0.28
Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort study 0.28
2 0.46
Prevalence of non-communicable disease risk factors and chronic conditions among middle-aged and older adults in extreme poverty: a nationally representative cross-sectional study in India 0.13
Implications of progressive lung damage and post-tuberculosis sequelae for the health benefits of prompt tuberculosis treatment in high HIV prevalence settings: a mathematical modelling analysis 0.33
1 0.86
High-sensitivity C-reactive protein, LDL cholesterol, lipoprotein(a) and 30-year risk of stroke in healthy women: a prospective, longitudinal cohort study 0.86
10 2.00
Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation 0.03
Endovascular Therapy for Post-Thrombotic Syndrome — A Randomized Trial 0.05
Angiography-Derived Fractional Flow Reserve to Guide PCI 0.05
Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation 0.09
Medical Management and Revascularization for Asymptomatic Carotid Stenosis 0.02
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke 0.30
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis 0.05
Home-Based Care for Hypertension in Rural South Africa 0.24
Apixaban for Extended Treatment of Provoked Venous Thromboembolism 0.96
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy 0.21
6 3.28
Occupational inhaled exposures and risk of interstitial lung abnormalities in individuals with potential familial susceptibility to pulmonary fibrosis 0.60
Correlates of 5-year decline in 6-min walk distance in the COPDGene cohort 0.06
Atomoxetine plus oxybutynin for obstructive sleep apnoea: a randomised-controlled trial with detailed pathophysiology 1.00
Acetazolamide to prevent ventilatory drive withdrawal in REM sleep apnoea: a randomised controlled trial 1.00
Loop gain predicts residual sleep apnoea among people using positive airway pressure 0.25
Circulating miRNAs and childhood asthma ICS response: a stratified analysis in the intervention arm of an RCT with vitamin D effect modification 0.37

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.